Analysis BioNTech’s Buyback Can’t Lift the Stock — Now the August 4 Numbers Have to Do the Heavy Lifting
The arithmetic of BioNTech’s share repurchase is straightforward on paper: a program of up to 24.9 million shares, capped at 10 percent of share capital, running from June 2026 through...